相关实验视频

Updated: Jun 12, 2025

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

lncRNA PTCSC1 在HCT116和SW480细胞中通过FOXO3a通路促进TRAIL抵抗

Changcheng Wang¹, Jia Guo², Zengan Wu³

¹General Surgery Diagnosis and Treatment of Diseases and Comprehensive Treatment of Tumor, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Haidian District, Beijing 100091, China.

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer

|June 10, 2025

概括

长非编码RNA PTCSC1过度表达通过DR4/AKT/FOXO3a通路抑制亡,促进结肠直肠癌 (CRC) 抵抗TNF相关的亡诱导连接体 (TRAIL) 疗法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

结肠直肠癌 (CRC) 是一个重大的全球健康挑战,死亡率高.
与TNF相关的诱导亡联体 (TRAIL) 疗法显示出有前途,但在许多CRC患者中面临阻力.
长非编码RNA PTCSC1在CRC中TRAIL抗性的作用在很大程度上仍未被阐明.

研究的目的:

研究PTCSC1在TRAIL抗性结直肠癌 (CRC) 中的作用.
探索导致CRC中PTCSC1-介导的TRAIL抗性的潜在分子机制.

主要方法:

在TRAIL敏感和TRAIL抗性CRC细胞系中对PTCSC1表达的比较分析 (HCT116,SW480,HT-29,caco-2).
评估PTCSC1对TRAIL诱导的亡的影响.
研究PTCSC1对死亡受体4 (DR4) 的表达以及AKT和FOXO3a信号通路的激活的影响.

主要成果:

发现PTCSC1在与TRAIL敏感细胞相比,在抗TRAIL的CRC细胞中过度表达.
增加的PTCSC1表达抑制了TRAIL诱导的亡,而减少的PTCSC1表达增强了它.
观察到PTCSC1降低DR4表达的调节,并提高AKT和FOXO3a激活的调节.

结论:

PTCSC1表达水平与CRC中对TRAIL诱导的亡的敏感性相关.
通过调节DR4/AKT/FOXO3a信号通路,PTCSC1有助于CRC中的TRAIL阻力.
向PTCSC1可能提供一种治疗策略,以克服结直肠癌中TRAIL抗性.

更多相关视频

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...